- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.54 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x DME: DECAMETHONIUM ION(Non-covalent)
DME.4: 11 residues within 4Å:- Chain A: Y.67, W.81, G.115, Y.118, E.196, W.276, F.327, F.328, Y.331, H.437, G.438
10 PLIP interactions:10 interactions with chain A- Hydrophobic interactions: A:W.81, A:F.327, A:F.327, A:F.327, A:F.328, A:Y.331
- Salt bridges: A:E.196
- pi-Cation interactions: A:W.81, A:W.81, A:W.276
DME.18: 11 residues within 4Å:- Chain B: Y.67, W.81, G.115, Y.118, E.196, W.276, F.327, F.328, Y.331, H.437, G.438
10 PLIP interactions:10 interactions with chain B- Hydrophobic interactions: B:W.81, B:F.327, B:F.327, B:F.327, B:F.328, B:Y.331
- Salt bridges: B:E.196
- pi-Cation interactions: B:W.81, B:W.81, B:W.276
- 20 x SO4: SULFATE ION(Non-functional Binders)
SO4.5: 3 residues within 4Å:- Chain A: H.403, N.522, Q.523
Ligand excluded by PLIPSO4.6: 5 residues within 4Å:- Chain A: N.421, H.422, N.503, T.504, E.505
Ligand excluded by PLIPSO4.7: 5 residues within 4Å:- Chain A: P.18, V.19, L.20, K.130, Y.131
Ligand excluded by PLIPSO4.8: 6 residues within 4Å:- Chain A: R.286, S.356, V.357, P.358, H.359, H.395
Ligand excluded by PLIPSO4.9: 4 residues within 4Å:- Chain A: S.234, A.236, E.237, R.240
Ligand excluded by PLIPSO4.10: 3 residues within 4Å:- Chain A: V.509, H.510, Q.511
Ligand excluded by PLIPSO4.11: 4 residues within 4Å:- Chain A: K.343, N.379, N.380, G.381
Ligand excluded by PLIPSO4.12: 3 residues within 4Å:- Chain A: N.254, S.255, D.256
Ligand excluded by PLIPSO4.13: 4 residues within 4Å:- Chain A: Q.65, S.88, E.89, P.268
Ligand excluded by PLIPSO4.14: 3 residues within 4Å:- Chain A: D.339, S.340, E.341
Ligand excluded by PLIPSO4.19: 3 residues within 4Å:- Chain B: H.403, N.522, Q.523
Ligand excluded by PLIPSO4.20: 5 residues within 4Å:- Chain B: N.421, H.422, N.503, T.504, E.505
Ligand excluded by PLIPSO4.21: 5 residues within 4Å:- Chain B: P.18, V.19, L.20, K.130, Y.131
Ligand excluded by PLIPSO4.22: 6 residues within 4Å:- Chain B: R.286, S.356, V.357, P.358, H.359, H.395
Ligand excluded by PLIPSO4.23: 4 residues within 4Å:- Chain B: S.234, A.236, E.237, R.240
Ligand excluded by PLIPSO4.24: 3 residues within 4Å:- Chain B: V.509, H.510, Q.511
Ligand excluded by PLIPSO4.25: 4 residues within 4Å:- Chain B: K.343, N.379, N.380, G.381
Ligand excluded by PLIPSO4.26: 3 residues within 4Å:- Chain B: N.254, S.255, D.256
Ligand excluded by PLIPSO4.27: 4 residues within 4Å:- Chain B: Q.65, S.88, E.89, P.268
Ligand excluded by PLIPSO4.28: 3 residues within 4Å:- Chain B: D.339, S.340, E.341
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Dym, O. et al., The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex. Protein Sci. (2016)
- Release Date
- 2016-03-30
- Peptides
- Acetylcholinesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.54 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 2 x DME: DECAMETHONIUM ION(Non-covalent)
- 20 x SO4: SULFATE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Dym, O. et al., The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex. Protein Sci. (2016)
- Release Date
- 2016-03-30
- Peptides
- Acetylcholinesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
A